deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04844970

Anamorelin Study for Advanced Pancreatic Cancer

A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer

Sponsor: Helsinn Healthcare SA

Conditions Metastatic Pancreatic Cancer
Interventions Anamorelin Hydrochloride Placebo
Updated 10 times since 2021 Last updated: Nov 3, 2025 Started: Apr 1, 2023 Primary completion: Nov 7, 2023 Completion: Nov 7, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study closure was initiated by the financial sponsor and agreed upon by the site PI. The study is closing because of low enrollment and insufficient funds.

Other terminated trials from Helsinn Healthcare SA

More terminations from Helsinn Healthcare SA

Other Metastatic Pancreatic Cancer trials with similar outcome

Browse all Metastatic Pancreatic Cancer trials

This PHASE2 trial investigates Metastatic Pancreatic Cancer and is currently terminated or withdrawn. Helsinn Healthcare SA leads this study, which shows 10 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2021 – ~Oct 2021 · 5 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2023 · 13 months · monthly snapshotRecruiting~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Mar 2024 · 6 months · monthly snapshotRecruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2025 · 15 months · monthly snapshotRecruiting~Dec 2025 – present · 9 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Sep 2024 — Dec 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  5. Sep 2023 — Mar 2024 [monthly]

    Recruiting PHASE2

▶ Show 5 earlier versions

  1. Apr 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  2. Mar 2022 — Apr 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Jan 2022 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE2

  4. Oct 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

  5. May 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Helsinn Healthcare SA
  • Lahey Clinic
  • Quartesian LLC
Data source: Lahey Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations